CD4 and fungal infectious disease: Data from the ACTG A5164 [12] study suggest that, globally, for fungal infections and/or CD4+ T-cell count lower than 50 cells/μL, an early initiation of cART (median 12 days) significantly reduces risk for disease progression and death compared with a later start of cART (median 45 days), indicating that even a few weeks of earlier cART could be beneficial in antiretroviral-naïve, HIV-infected individuals diagnosed with these opportunistic infections.